tirzepatide causing fatigue Does Make You Tired? 20 Possible Tirzepatide Side Effects

In patients with type 2 diabetes and high cardiovascularrisk, clinical trials have shown that GLP-1 receptor agonistsreduce the incidence of major adverse cardiovascular events.The effect of tirzepatide a dual incretin agonist of theGLP-1 and GIP receptors on cardiovascular outcomes isuncertain. In theSURPASS-CVOTtrial, patients40 years of age or older with type 2 diabetes, a BMIof at least 25, and atherosclerotic cardiovascular disease wererandomly assigned to receive a weekly subcutaneous injectionof tirzepatide (up to 15 mg) or dulaglutide (1.5 mg), a GLP-1receptor agonist that has been shown to reduce the incidenceof cardiovascular events

Have you heard of Tirzepatide

Tirzepatide could result in net lifetime health care costs of more than $16 trillion in the U.S

A 2024 RCT found semaglutide reduced hip bone density by 2.6% and lumbar spine by 2.1% in one year

The SGI Standards are International Standards for Gender Equality and standard regulations that focus on the management of equal opportunities in organisations, either public or private.